These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23192217)

  • 21. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
    Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
    J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Machine learning derived input-function in a dynamic
    Kuttner S; Wickstrøm KK; Kalda G; Dorraji SE; Martin-Armas M; Oteiza A; Jenssen R; Fenton K; Sundset R; Axelsson J
    Biomed Phys Eng Express; 2020 Jan; 6(1):015020. PubMed ID: 33438608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of the reference region method for dual pharmacokinetic modeling using Gd-DTPA/MRI and (18) F-FDG/PET.
    Poulin É; Lebel R; Croteau É; Blanchette M; Tremblay L; Lecomte R; Bentourkia M; Lepage M
    Magn Reson Med; 2015 Feb; 73(2):740-8. PubMed ID: 24604379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the optimal acquisition protocol of breath-hold PET/CT for the diagnosis of thoracic lesions.
    Mitsumoto K; Abe K; Sakaguchi Y; Zhang T; Tachiya Y; Ohya N; Baba S; Sasaki M
    Nucl Med Commun; 2011 Dec; 32(12):1148-54. PubMed ID: 21968434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography.
    Goerres GW; Schuknecht B; Schmid DT; Stoeckli SJ; Hany TF
    Clin Imaging; 2008; 32(6):431-7. PubMed ID: 19006770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of multiple time point dynamic positron emission tomography/computed tomography in patients with oral/head and neck cancer does not predictably identify metastatic cervical lymph nodes.
    Carlson ER; Schaefferkoetter J; Townsend D; McCoy JM; Campbell PD; Long M
    J Oral Maxillofac Surg; 2013 Jan; 71(1):162-77. PubMed ID: 22742956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
    Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
    J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
    An YS; Sheen SS; Oh YJ; Hwang SC; Yoon JK
    Ann Nucl Med; 2007 Dec; 21(10):585-92. PubMed ID: 18092135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
    Morbelli S; Conzi R; Campus C; Cittadini G; Bossert I; Massollo M; Fornarini G; Calamia I; Marini C; Fiz F; Ghersi C; Derchi LE; Sambuceti G
    Cancer Imaging; 2014 Apr; 14(1):10. PubMed ID: 25609564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
    Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Coleman RE
    Radiology; 2007 Jul; 244(1):263-72. PubMed ID: 17495174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different intravenous contrast media concentrations do not affect clinical assessment of 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans in an intraindividual comparison.
    Prechtel HW; Verburg FA; Palmowski M; Krohn T; Pietsch H; Kuhl CK; Mottaghy FM; Behrendt FF
    Invest Radiol; 2012 Sep; 47(9):497-502. PubMed ID: 22820678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorodeoxyglucose-PET/Computed Tomography-Guided Biopsy.
    Cerci JJ; Tabacchi E; Bogoni M
    PET Clin; 2016 Jan; 11(1):57-64. PubMed ID: 26590444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does reducing CT artifacts from dental implants influence the PET interpretation in PET/CT studies of oral cancer and head and neck cancer?
    Nahmias C; Lemmens C; Faul D; Carlson E; Long M; Blodgett T; Nuyts J; Townsend D
    J Nucl Med; 2008 Jul; 49(7):1047-52. PubMed ID: 18552154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
    Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
    J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.